The hospital is too late. So they moved care home.

A care team that lives inside the living room

It is a Tuesday in rural North Carolina. A 68-year-old with COPD blows into a device the size of a deck of cards. Two hundred miles away, a NuvoAir clinician sees the numbers dip and picks up the phone - days before that dip would have become an ambulance.

That scene is the entire company in miniature. NuvoAir Medical is a virtual-first cardiopulmonary care company: connected hardware in the patient's hand, software reading the signal, and real clinicians acting on it. Heart and lung conditions - COPD, asthma, congestive heart failure - are managed where people actually live, not where they get admitted.

The company started life in Stockholm as a respiratory-tech startup and has since planted its center of gravity in Boston. It is small - around 71 people - but it sits in the middle of three things that rarely cooperate: medical devices, software, and the unglamorous business of getting paid for keeping people healthy.

Chronic lung disease is a slow emergency

Roughly 500 million people worldwide live with a chronic respiratory disease. Most of them are fine - until they are suddenly not. An exacerbation builds quietly over days, and the system tends to notice only at the expensive end of it: the emergency room, the inpatient bed, the readmission.

The data between appointments is the data nobody collects. A patient sees a pulmonologist a couple of times a year; the other 363 days are a blank chart. NuvoAir's founding observation was unfashionably simple - if you measure breathing at home, every day, you can act before the crisis instead of after it.

It sounds obvious. Obvious ideas, of course, are the ones everyone agrees with and nobody had bothered to build.

A company built from a childhood inhaler

Lorenzo Consoli did not arrive at respiratory care through a spreadsheet. He had severe asthma as a child, serious enough to put him in the hospital. His grandmother died of COPD. His young son has asthma too. The disease is, for him, a family fact.

In 2012 he worked on Novartis's digital health team, where he saw that digital biomarkers - a cough pattern, a lung-function trend - could predict where a patient was heading. He left to build the thing himself, founding NuvoAir around 2015-2016.

The bet was that connected measurement plus a human care team beats either one alone. A device without clinicians is a gadget. Clinicians without daily data are guessing. NuvoAir wagered the company on doing both, and on a harder business model: getting paid for outcomes, not visits.

Small device, serious clearance

The flagship is the Air Next, a smartphone-connected spirometer small enough to ignore on a kitchen table. In January 2024 it earned FDA 510(k) clearance for full in-home spirometry - meaning patients can run comprehensive lung-function tests at home, with the results feeding a clinical team in real time. That clearance is the difference between a wellness toy and a regulated medical instrument.

A spirometer you could lose in a sock drawer, cleared to do the work of a clinic's pulmonary lab.

The numbers that earn the pitch

Plenty of digital health companies promise to save the system money. NuvoAir put it in a study. The PROMISE interim report compared patients in the NuvoAir Home Service against matched controls on standard care, and the results are the kind that finance teams actually read.

The customer list backs the science. Provider partners have included Boston Children's Hospital and Dartmouth-Hitchcock Medical Center; pharma names like Roche, Regeneron and Novartis have run trials on the platform. In 2024 the company pushed into care delivery with Cary Medical Management in North Carolina and Privia Medical Group in Georgia.

Make every moment count

NuvoAir's stated tagline is "Make Every Moment Count," which from most companies would be wall art. Here it has teeth: the entire model is about the moments between appointments, the slow days where an exacerbation quietly builds.

The mission is to let people with chronic heart and lung disease manage their health proactively from home, so that a clinician can step in early - before the hospital, not after it. It is care designed around the 363 blank days, not the two appointments.

The next ambulance that doesn't get called

Healthcare is slowly, grudgingly moving from paying for visits to paying for outcomes. That shift is exactly the ground NuvoAir built on. As value-based contracts spread and home-based care becomes normal rather than novel, a company that can prove fewer hospitalizations - in a study, with a cleared device - is holding a useful hand.

Back to that Tuesday in North Carolina. The patient blows into the little device again. The numbers hold steady. No phone call, no ambulance, no admission - just an ordinary day at home. The crisis that didn't happen is invisible by design. That is the product working exactly as intended, and it is the future NuvoAir is quietly betting the whole company on.